Susquehanna International Group
INKT icon

Susquehanna International Group’s MiNK Therapeutics INKT Stock Holding History

Susquehanna International Group’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,983
Closed -$27.1K – 12613
2024
Q1 		$27.1K Buy
+2,983
New +$27.7K ﹤0.01% 11745

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's INKT Position: Q2 2024 in Review

Susquehanna International Group sold out of MiNK Therapeutics (INKT) in Q2 2024, closing a stake of 2,983 shares — an estimated $27.1K sold.

Susquehanna International Group first reported a position in INKT in Q1 2024 and held it in 1 quarter. The position peaked at $27.1K in Q1 2024. 29 funds tracked by Wall St. Rank hold INKT as of Q2 2024.

  • Susquehanna International Group reported no remaining MiNK Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 2,983 MiNK Therapeutics shares in Q2 2024, an estimated $27.1K.
  • Susquehanna International Group first reported a position in MiNK Therapeutics in Q1 2024 and held it in 1 quarter.
  • Susquehanna International Group's MiNK Therapeutics position peaked at $27.1K in Q1 2024.
  • 29 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.